Downtown Lynchburg to add Western charm
The Trading Post, a new coffee shop and convenience store, is opening in the space where Mark Smith once housed many of his antique cars before he died.
Source: newsadvance.com
📰 Peter Traber News
Peter Traber News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Peter Traber. Real-time updates on events, politics, business and more.
Swedish Orphan Biovitrum : 22 March – Phase 3 study results SEL-212 (transcript)
You efficacy and point and were highly statistically significant, which of course is the first thing. 0:0:6.780 --> 0:0:37.30 Peter... | March 27, 2023
Source: marketscreener.com
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB (2)
--75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of...
Source: europapress.es
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB (3)
--75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of...
Source: europapress.es
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB
/PRNewswire/ -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Sobi®, today announced positive topline results from the Phase 3 DISSOLVE I & II placebo...
Source: prnewswire.com
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB (1)
--75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of...
Source: europapress.es
Selecta Biosciences, Inc. (NASDAQ:SELB) Q4 2022 Earnings Call Transcript
Operator: Good morning, and welcome to the Selecta Bio Fourth Quarter 2022 Earnings Release Conference Call. Please note this event is being recorded.
Source: insidermonkey.com
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABBV) - The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Pfizer, Inc. (NYSE: PFE) and Myovant Sciences (NYSE: MYOV) announced FDA approval for once-daily Myfembree, relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg, for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months. The companies said they will jointly commercialize Myfembree in the U.S. Myfembree is expected to be available in June. Pfizer shares edged down 0.15% to $38.86 in after-hou...
Source: benzinga.com